On September 4, 2024, HAYA Therapeutics, a pioneering biotechnology company that uses precise RNA guidance to regulate genome targeting therapy for chronic diseases, announced the signing of a multi-year cooperation agreement with Eli Lilly. Both parties will utilize HAYA's advanced RNA guided regulatory genome platform to support preclinical drug discovery for obesity and related metabolic diseases. The partner will identify multiple RNA targets derived from the regulatory genome to treat these chronic diseases.

According to the terms of the cooperation agreement, HAYA will receive a down payment, including equity investment, and is eligible to receive up to $1 billion in preclinical, clinical, and commercial milestone payments, as well as royalties for product sales.

HAYA's proprietary regulatory genome discovery platform can identify long non coding RNA (lncRNA) targets specific to tissues, diseases, and cells, and develop treatment methods targeting RNA, which may have better efficacy and lower toxicity compared to current treatment methods, thereby reshaping the cellular state driving diseases. This collaboration will utilize HAYA's full stack regulatory genome platform to identify, characterize, and validate multiple novel lncRNA targets for the development of new therapies for the treatment of obesity and related metabolic disorders.

About HAYA Therapeutics

HAYA Therapeutics is a precision medicine company dedicated to developing programmable therapeutic drugs targeting regulatory RNAs from the 'dark genome' to reshape the state of pathogenic cells for a wide range of diseases, including cardiovascular and metabolic diseases as well as cancer. The company utilizes its innovative platform to gain a deeper understanding of disease cell states and the biology of long non coding RNAs (lncRNAs) that regulate these states. HAYA's leading candidate drug HTX001 is currently being developed for the treatment of heart failure. HAYA is still developing a series of precise treatment methods targeting lncRNA for cell specific therapy of diseases in other tissues.